Friday 16 October 2026
Export CUE’s income statement to Excel — free account
Cue Biopharma, Inc.
Cue Biopharma, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $27.5 million, up 195.7% from fiscal 2024. In the quarter to June 2026, revenue grew 166.7%, EPS fell 793.2% and free cash flow fell 742.7%, each against the same quarter a year earlier. Revenue growth for three consecutive years, operating cash flow growth for three; insiders bought in the last twelve months.
16.96
1.71
−9.16%
Follow CUE
| Older periods | Sep '25 | Dec '25 | Mar '26 | Jun '26 | |
|---|---|---|---|---|---|
P/E ratio |
+8 more quarters Free account |
0.00 | 0.00 | 0.00 | 0.00 |
P/S ratio |
10.20 | 1.05 | 1.01 | 5.31 | |
P/FCF ratio |
0.00 | 0.00 | 0.00 | 0.00 | |
P/Operating CF |
(8.03) | (26.83) | (3.03) | (6.90) | |
P/B ratio |
5.47 | 1.09 | 1.54 | 86.63 | |
Price to Tangible BV |
5.54 | 1.10 | 1.55 | 93.73 | |
EV/Sales |
7.56 | 0.08 | 0.53 | 4.90 | |
EV/EBITDA |
0.00 | 0.00 | 0.00 | 0.00 | |
EV/Operating CF |
(1.81) | (0.11) | (0.71) | (3.68) | |
EV/FCF |
(1.80) | (0.10) | (0.71) | (3.68) | |
Quick Ratio |
1.34 | 2.50 | 3.08 | 1.07 | |
Current Ratio |
1.66 | 2.74 | 3.57 | 1.25 | |
Net Debt/EBITDA |
2.44 | (10.72) | 3.64 | 0.20 | |
Debt/Assets |
5.21% | 0.00% | 0.00% | 0.00% | |
Debt/Equity |
0.12 | 0.00 | 0.00 | 0.00 | |
Asset Turnover |
0.19 | 0.74 | 1.23 | 1.05 | |
Operating CF/Net income |
1.21 | (0.68) | 2.11 | 0.19 | |
Capex/Depreciation |
(0.22) | 0.03 | (0.21) | 0.00 | |
Interest Coverage |
(101.27) | 18.14 | (1,338.25) | (17,539.00) | |
Research and Development Expense of Revenue |
221.22% | 75.34% | 121.30% | 622.15% | |
Selling, General and Administrative Expense of Revenue |
229.83% | 15.74% | 73.02% | 591.15% | |
Intangible Assets out of Total Assets |
0.00 | 0.00 | 0.00 | 0.00 | |
Share Based Compensation of Revenue |
71.34% | 2.78% | 0.84% | 302.63% | |
Graham Net Nets |
0.10 | 0.73 | 0.52 | (0.01) | |
Graham Number |
0.00 | 0.00 | 0.00 | 0.00 | |
Earnings Yield |
(64.04%) | (105.02%) | (80.93%) | (85.62%) | |
Free Cash Flow Yield |
(41.13%) | (75.61%) | (74.05%) | (25.05%) | |
Revenue per Share |
0.64 | 6.96 | 1.18 | 1.24 | |
Operating CF per Share |
(2.69) | (0.34) | (2.28) | (4.57) | |
Capex per Share |
0.01 | 0.01 | (0.03) | 0.00 | |
Free Cash Flow per Share |
(2.68) | (0.33) | (2.30) | (4.57) | |
Cash per Share |
6.08 | 8.95 | 3.63 | 2.75 | |
Shareholders Equity per Share |
3.94 | 8.38 | 4.49 | 0.36 | |
Interest Debt per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Book value per Share |
3.94 | 8.38 | 4.49 | 0.36 | |
Free Cash Flow |
(9.00) | (1.06) | (11.06) | (29.00) | |
Working Capital |
10.30 | 23.49 | 19.00 | 5.41 | |
Capital Expenditures |
0.02 | 0.02 | (0.12) | 0.00 | |
Net Current Asset Value |
7.42 | 21.20 | 17.12 | (1.77) | |
EV/EBIT |
0.00 | 0.00 | 0.00 | 0.00 | |
Capex to Sales |
(0.01) | 0.00 | 0.02 | 0.00 | |
Price to Operating Income |
0.00 | 0.00 | 0.00 | 0.00 | |
| Other line items | |||||
Average Receivables |
1.12 | 4.35 | 3.15 | 2.95 | |
Average Payables |
4.41 | 3.39 | 3.56 | 3.69 | |
Average Assets |
38.23 | 37.20 | 26.57 | 35.71 | |
Average Common Equity |
19.31 | 21.97 | 14.09 | 10.23 |
Columns are period end dates